Structure
SAR-260301, inhibitor
SAR-260301
Purity
98.00%
Synonyms
SAR-260301; inhibitor
Purity/Purification
98.00%
Form/Format
Solid. Powder
Solubility
DMSO: 125mg/mL (352.71mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C19H22N4O3
SMILES
O=C1N=C(CC(N2[C@@H](C)CC3=C2C=CC=C3)=O)NC(N4CCOCC4)=C1
CAS Number
1260612-13-2
Target & IC50
PI3Kbeta: ic50 23nM
PI3Kdelta: ic50 468nM
PI3Kalpha: ic50 1539nM
PI3Kgamma: ic50 10000nM
Vps34: ic50 183nM
PI3KC2gamma: ic50 3812nM
pAkt: ic50 49nM
DNA-PK: ic50 2000nM
PI3Kdelta: ic50 468nM
PI3Kalpha: ic50 1539nM
PI3Kgamma: ic50 10000nM
Vps34: ic50 183nM
PI3KC2gamma: ic50 3812nM
pAkt: ic50 49nM
DNA-PK: ic50 2000nM
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
-80 degree C for 2 years in solvent
Structure
Structure
Related Product Information for SAR-260301, inhibitor
SAR-260301 is an orally available and selective inhibitor of PI3Kbeta (IC50: 23nM).
Product Categories/Family for SAR-260301, inhibitor
References
Certal V, et al. Discovery and optimization of pyrimidone indoline amide PI3Kbeta inhibitors for the treatment,of phosphatase and tensin homologue (PTEN)-deficient cancers. J Med Chem. 2014 Feb 13;57(3):903-20.
Certal V, et al. Discovery and optimization of pyrimidone indoline amide PI3Kbeta inhibitors for the treatment,of phosphatase and tensin homologue (PTEN)-deficient cancers. J Med Chem. 2014 Feb 13;57(3):903-20.
Bonnevaux H, et al. Concomitant Inhibition of PI3Kbeta and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma treatment, Preclinical Assessment of SAR260301 Oral PI3Kbeta-Selective Inhibitor. Mol Cancer Ther. 2016 Jul;15(7):1460-71.
Bonnevaux H, et al. Concomitant Inhibition of PI3Kbeta and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma treatment, Preclinical Assessment of SAR260301 Oral PI3Kbeta-Selective Inhibitor. Mol Cancer Ther. 2016 Jul;15(7):1460-71.
Certal V, et al. Discovery and optimization of pyrimidone indoline amide PI3Kbeta inhibitors for the treatment,of phosphatase and tensin homologue (PTEN)-deficient cancers. J Med Chem. 2014 Feb 13;57(3):903-20.
Bonnevaux H, et al. Concomitant Inhibition of PI3Kbeta and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma treatment, Preclinical Assessment of SAR260301 Oral PI3Kbeta-Selective Inhibitor. Mol Cancer Ther. 2016 Jul;15(7):1460-71.
Bonnevaux H, et al. Concomitant Inhibition of PI3Kbeta and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma treatment, Preclinical Assessment of SAR260301 Oral PI3Kbeta-Selective Inhibitor. Mol Cancer Ther. 2016 Jul;15(7):1460-71.
Similar Products
Product Notes
The SAR-260301 (Catalog #AAA5755501) is an Inhibitor and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "SAR-260301, Inhibitor" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
